Hypofractionated Radiotherapy for Localized Prostate Cancer (With CyberKnife or With IMRT)
This study has been completed.
Sponsor:
Stanford University
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT00855647
First received: March 2, 2009
Last updated: June 1, 2010
Last verified: June 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To demonstrate that a hypo-fractionated course of radiotherapy (ie. an accelerated radiotherapy course where fewer but larger doses of radiotherapy are given) is both safe and effective in the treatment of low-risk localized prostate cancer.
Condition | Intervention | Phase |
---|---|---|
Prostatic Neoplasms |
Procedure: Hypo-fractionated Radiotherapy |
Phase 2 |
Study Type: | Interventional |
Study Design: | Allocation: Non-Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
Official Title: | Hypofractionated Radiotherapy for Localized Prostate Cancer (With CyberKnife or With IMRT) |
Resource links provided by NLM:
Further study details as provided by Stanford University:
Primary Outcome Measures:
- PSA response that achieves a stable nadir over time. [ Time Frame: unknown ] [ Designated as safety issue: No ]
Estimated Enrollment: | 99999 |
Study Start Date: | August 2003 |
Study Completion Date: | July 2009 |
Primary Completion Date: | March 2009 (Final data collection date for primary outcome measure) |
Eligibility
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:- Eligible patients will have clinical stage T1c through T2b, initial PSA level <10 and a biopsy Gleason score of 3+3 or 3+4 with fewer than 50% of biopsy cores involved.
- Patients who have had any form of prior curative treatment (surgery, radiotherapy, cryotherapy) will not be eligible. A prior course of hormone therapy of less than 3 months duration will be allowed.
- Adult men will be considered.
- No life expectancy restrictions will apply.
- Performance Status will not be considered.
- No requirements for organ or marrow function will be made
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:- No prior prostate treatment will be allowed.
- The use of other concurrent Investigational Agents will not be allowed.
- No exclusion requirements due to co-morbid disease or incurrent illness.
- No requirements regarding history of allergic reactions.
- Pregnancy or nursing patients is not applicable (ie. patients are male).
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00855647
Locations
United States, California | |
Stanford University School of Medicine | |
Stanford, California, United States, 94305 |
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: | Christopher R. King | Stanford University |
More Information
No publications provided
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on September 26, 2012
No publications provided
Responsible Party: | Christopher R. King, Stanford University School of Medicine |
ClinicalTrials.gov Identifier: | NCT00855647 History of Changes |
Other Study ID Numbers: | SU-11022007-792, 79432, PROS0020 |
Study First Received: | March 2, 2009 |
Last Updated: | June 1, 2010 |
Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
Neoplasms Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms |
Neoplasms by Site Genital Diseases, Male Prostatic Diseases |
ClinicalTrials.gov processed this record on September 26, 2012